Skip to main content

Table 2 Comparisons of baseline characteristics between training set and testing set

From: Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China

Characteristics

Training set (n = 279)

No. (%) / Median (IQR)

Testing set (n = 120)

No. (%) / Median (IQR)

P

Cardiac injury

113(40.5)

48(40.0)

0.925

Gender

  

0.993

 Male

151(54.1)

65(54.2)

 

 Female

128(45.9)

55(45.8)

 

Age (years)

  

0.593

 Age < 60

150(53.8)

68(56.7)

 

 Age ≥ 60

129(46.2)

52(43.3)

 

Smoking history

47(16.8)

20(16.7)

0.965

History of hypertension

47(16.8)

20(16.7)

0.965

History of diabetes

21(7.5)

8(6.7)

0.761

WBC (109/L)

10.34(2.23–40.62)

8.835(2.005–25.98)

0.395

RBC (1012/L)

2.2(1.7–2.66)

2.185(1.7–2.58)

0.827

Hb (g/L)

70(56.2–86.2)

69.85(56.725–84.45)

0.946

PLT (109/L)

37(20–71)

40(21-81.5)

0.307

BM blast ratio (%)

59.5(35.5–81.5)

59.25(35.75–78.05)

0.740

Gene mutations

   

 NPM1

43(15.4)

20(16.7)

0.753

 CEBPA

31(11.1)

11(9.2)

0.562

 FLT3

47(16.8)

20(16.7)

0.965

 C-kit

12(4.3)

3(2.5)

0.562

 TP53

17(6.1)

7(5.8)

0.920

 RUNX1

11(3.9)

6(5.0)

0.632

 Ras

16(5.7)

4(3.3)

0.313

 TET2

16(5.7)

10(8.3)

0.335

 IDH

25(9.0)

12(10.0)

0.743

 WT1

165(59.1)

70(58.3)

0.881

 JAK2

6(2.2)

5(4.2)

0.427

 AML1-ETO

19(6.8)

10(8.3)

0.591

 CBFB-MYH11

13(4.7)

4(3.3)

0.548

 BCR-ABL

9(3.2)

5(4.2)

0.864

 MLL

14(5.0)

9(7.5)

0.329

Cytogenetics

   

 Abnormal karyotype

149(53.4)

60(50.0)

0.532

 Complex karyotype

44(15.8)

27(22.5)

0.107

 Monosomy karyotype

28(10.0)

16(13.3)

0.335

 t8-21

15(5.4)

8(6.7)

0.612

 inv16

12(4.3)

3(2.5)

0.562

 t9-22

4(1.4)

1(0.8)

0.997

 plus8

25(9.0)

13(10.8)

0.559

 del5q

22(7.9)

7(5.8)

0.469

 del7

17(6.1)

8(6.7)

0.828

 del17p

9(3.2)

5(4.2)

0.864

Abnormal NT-proBNP

70(25.1)

31(25.8)

0.875

Echocardiogram indexes

   

 LA (mm)

34(30–38)

34(30–38)

0.823

 LV (mm)

45(42–48)

46(42.25-48)

0.678

 IVS (mm)

10(9–11)

10(9–11)

0.312

 EDV (ml)

97(78–111)

97(82.25–113)

0.930

 ESV (ml)

31(25–40)

30(24.25-41)

0.704

 SV (ml)

64(54–77)

68(56-78.75)

0.256

 EF (%)

65(60–70)

65.5(60–71)

0.839

  1. NPM1: nucleophosmin 1; CEBPA: CCAAT/enhancer-binding protein alpha; FLT3: Fms-like tyrosine kinase 3; TP53, Tumor Protein P53; RUNX1: runt-related transcription factor 1; TET2: tet methylcytosine dioxygenase 2; IDH: Isocitrate dehydrogenase; WT1: Wilm tumor gene1; JAK2: Janus kinase 2; AML1-ETO: acute myeloid leukemia 1 Eight-twenty-one; CBFB-MYH11: core-binding factor, beta subunit-myosin heavy chain 11; BCR-ABL: breakpoint cluster region-Abelson; MLL: Mixed lineage leukemia; NT-pro BNP: N-terminal pro-B-type natriuretic peptide; WBC: White blood cells; RBC: Red blood cells; Hb: Hemoglobin; PLT: Platelets; LA: Left atrium; LV: Left ventricle; IVS: Interventricular septum; EDV: End-diastolic volume; ESV: End-systolic volume; SV: stroke volume; EF: Ejection fraction; BM: bone marrow
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us